Christophe Hezode

Summary

Country: France

Publications

  1. doi request reprint Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Liver Int 32:32-8. 2012
  2. doi request reprint Direct-acting antiviral (DAA) actions in treatment-naïve patients
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Clin Res Hepatol Gastroenterol 35:S52-8. 2011
  3. ncbi request reprint Management of anaemia and other treatment complications
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France Electronic address
    Dig Liver Dis 45:S337-42. 2013
  4. ncbi request reprint Oral combination therapy: future hepatitis C virus treatment?
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Hepatol 55:933-5. 2011
  5. ncbi request reprint [Chronic hepatitis B: antiviral treatment guidelines]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, AP HP, Universite Paris 12, 94000 Creteil
    Rev Prat 60:751-8. 2010
  6. ncbi request reprint Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Jean Pierre Bronowicki
    Department of Hepatology and Gastroenterology, INSERM U724, CHU de Nancy, Vandoeuvre les Nancy, France
    Gastroenterology 131:1040-8. 2006
  7. ncbi request reprint [Treatment of patients with chronic hepatitis C who never had been treated]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, Universite Paris XII, AP HP, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil
    Gastroenterol Clin Biol 26:B38-49. 2002
  8. pmc Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay
    Karine Gourlain
    Department of Virology, INSERM U635, Creteil, France
    J Clin Microbiol 43:1669-73. 2005
  9. doi request reprint Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
  10. doi request reprint High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial)
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, INSERM U955, Creteil, France
    Gastroenterology 141:119-27. 2011

Detail Information

Publications30

  1. doi request reprint Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Liver Int 32:32-8. 2012
    ..However, approximately 5% of rashes were severe, and a few cases were classified as severe cutaneous adverse reactions leading to treatment discontinuation...
  2. doi request reprint Direct-acting antiviral (DAA) actions in treatment-naïve patients
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Clin Res Hepatol Gastroenterol 35:S52-8. 2011
    ..Also, the use of TVR and BOC is being enhanced by the acquisition of further data on predictors of SVR, thereby increasing patients'chances of being cured of their HCV infection...
  3. ncbi request reprint Management of anaemia and other treatment complications
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France INSERM U955, Creteil, France Electronic address
    Dig Liver Dis 45:S337-42. 2013
    ..Successful treatment can be enhanced by a strong patient support network including a multidisciplinary team...
  4. ncbi request reprint Oral combination therapy: future hepatitis C virus treatment?
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Hepatol 55:933-5. 2011
    ....
  5. ncbi request reprint [Chronic hepatitis B: antiviral treatment guidelines]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, AP HP, Universite Paris 12, 94000 Creteil
    Rev Prat 60:751-8. 2010
    ..The other strategy is based on long-term administration of a nucleos (t) ide analogue with a potent antiviral activity and good patterns of resistance and safety (entecavir or tenofovir)...
  6. ncbi request reprint Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Jean Pierre Bronowicki
    Department of Hepatology and Gastroenterology, INSERM U724, CHU de Nancy, Vandoeuvre les Nancy, France
    Gastroenterology 131:1040-8. 2006
    ..We aimed to investigate the role of ribavirin in HCV clearance during therapy and to evaluate the consequences of ribavirin discontinuation in patients infected with genotype 1 hepatitis C who cleared HCV RNA at week 24...
  7. ncbi request reprint [Treatment of patients with chronic hepatitis C who never had been treated]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, Universite Paris XII, AP HP, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil
    Gastroenterol Clin Biol 26:B38-49. 2002
  8. pmc Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay
    Karine Gourlain
    Department of Virology, INSERM U635, Creteil, France
    J Clin Microbiol 43:1669-73. 2005
    ..These results emphasize the need for commercial HCV RNA quantification assays with a broader range of linear quantification, such as real-time PCR-based assays...
  9. doi request reprint Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  10. doi request reprint High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial)
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, INSERM U955, Creteil, France
    Gastroenterology 141:119-27. 2011
    ..The influence of genetic determinants in this context remains unknown...
  11. pmc Complex dynamics of hepatitis B virus resistance to adefovir
    Coralie Pallier
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Hepatology 49:50-9. 2009
    ..Whether these adefovir resistance-associated substitutions may confer cross-resistance to tenofovir in vivo will need to be determined...
  12. ncbi request reprint Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, AP HP, Universite Paris Est, INSERM U955, Creteil, France
    Gastroenterology 147:132-142.e4. 2014
    ..We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis...
  13. ncbi request reprint Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    Hepatology 42:63-71. 2005
    ..In conclusion, daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use...
  14. doi request reprint Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, AP HP, Universite Paris Est, INSERM U955, Creteil, France
    J Hepatol 59:434-41. 2013
    ..We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme...
  15. pmc Analysis of ribavirin mutagenicity in human hepatitis C virus infection
    Stephane Chevaliez
    Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    J Virol 81:7732-41. 2007
    ..This study strongly undermines the hypothesis whereby ribavirin acts as an HCV mutagen in vivo...
  16. pmc Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease
    Laetitia Barbotte
    Department of Virology, Hopital Henri Mondor, France
    Antimicrob Agents Chemother 54:2681-3. 2010
    ..5-fold increase in the replicon model. The replication capacity of a replicon harboring V36C was close to that of the wild-type protease. This case emphasizes the complexity of hepatitis C virus resistance to protease inhibitors...
  17. doi request reprint Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Henri Mondor Albert Chenevier, Creteil, France
    Gastroenterology 134:432-9. 2008
    ..Two recent studies indicate that endocannabinoids promote experimental steatosis via activation of hepatic CB1 receptors. We therefore investigated the impact of cannabis smoking on steatosis severity during CHC...
  18. ncbi request reprint Antiviral action of ribavirin in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Gastroenterology 126:703-14. 2004
    ..Our aim was to assess the antiviral action of ribavirin on hepatitis C virus (HCV) as a function of ribavirin pharmacokinetics and to evaluate the influence of this antiviral effect on IFN-alpha efficacy...
  19. doi request reprint Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis
    Aurélie Piodi
    French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, France
    Hepatology 48:16-27. 2008
    ..Importantly, we found no genetic or functional differences between genotype 3a core proteins from patients with and without HCV-induced steatosis...
  20. doi request reprint Association of caffeine intake and histological features of chronic hepatitis C
    Charlotte E Costentin
    AP HP, Service d hépatologie et de gastroentérologie, Groupe Hospitalier Henri Mondor Albert Chenevier, Creteil 94000, France
    J Hepatol 54:1123-9. 2011
    ..The aim of this study was to evaluate the impact of caffeine consumption on activity grade and fibrosis stage in patients with CHC...
  21. doi request reprint Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Hepatol 58:676-83. 2013
    ..The aim of the present study was to assess whether finite nucleoside/nucleotide analogue treatment duration could be envisaged during the patient's lifetime...
  22. ncbi request reprint Hepatitis C virus-induced hepatocellular steatosis
    Laurent Castera
    Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire, Bordeaux, France
    Am J Gastroenterol 100:711-5. 2005
    ..This review discusses current knowledge of HCV-induced steatosis and its relation to chronic HCV-associated liver disease...
  23. pmc Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    J Clin Microbiol 48:3641-7. 2010
    ..Overall, the CAP/CTM assay, version 2.0, is well suited to monitoring clinical HBV DNA levels according to current clinical practice guidelines...
  24. ncbi request reprint Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris XII, Creteil, France
    J Hepatol 46:791-6. 2007
    ..Some patients receiving adefovir at the approved dose of 10 mg daily for chronic hepatitis B have a "suboptimal" virological response characterized by a slow and moderate decrease in viral replication...
  25. ncbi request reprint [Chronic hepatitis C with repeatedly normal transaminase levels]
    Daniel Dhumeaux
    Service d Hépathologie et de Gastroentérologie, Hopital Henri Mondor, Universite Paris XII, AP HP, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Cr and eacuteteil, France
    Rom J Gastroenterol 11:129-33. 2002
  26. ncbi request reprint Sofosbuvir and ribavirin in HCV genotypes 2 and 3
    Stefan Zeuzem
    From the Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany S Z Royal Free Hospital and University College London School of Medicine, London G M D Tartu University Hospital, Tartu, Estonia R S Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy A M Medical University of Bialystok, Bialystok, Poland R F Gilead Sciences, Foster City, CA R H H, A I, E S, D M B, W T S, G M S, J G M Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm O W Academic Medical Center, Amsterdam H W R Medical University of Vienna, Vienna P F Hôpital Henri Mondor, Assistance Publique Hopitaux de Paris, Universite Paris Est, Inserm Unité 955, Creteil, France C H and Hospital Universitario Val d Hebron, Barcelona R E
    N Engl J Med 370:1993-2001. 2014
    ....
  27. doi request reprint Environmental factors as disease accelerators during chronic hepatitis C
    Ariane Mallat
    Department of Hepatology and Gastroenterology, INSERM U841, Groupe Hospitalier Henri Mondor Albert Chenevier, Créteil F 94000, France
    J Hepatol 48:657-65. 2008
    ..Altogether, patients should be informed of the deleterious impact of alcohol, tobacco and cannabis use and should be offered appropriate support to achieve abstinence...
  28. ncbi request reprint [Steasis and hepatitis C]
    Christophe Hezode
    Service d hépatologie et de gastroentérologie, Hopital Henri Mondor, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil
    Gastroenterol Clin Biol 27:1091-5. 2003
  29. ncbi request reprint [Pegylated interferons: pharmacological basis]
    Isabelle Macquin-Mavier
    Service de Pharmacologie Clinique, CHU Henri Mondor, Assistance Publique, Hopitaux de Paris, 94000 Creteil, France
    Gastroenterol Clin Biol 26:742-7. 2002
  30. ncbi request reprint Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, AP HP, Hopital Henri Mondor, Creteil, France
    Hepatology 36:374-80. 2002
    ..5 mg/h NA) that did not recur after a dose reduction. In conclusion, NA combined with albumin and furosemide appears effective and safe for the treatment of type 1 HRS...